van Hasselt J G Coen, Allegaert Karel, van Calsteren Kristel, Beijnen Jos H, Schellens Jan H M, Huitema Alwin D R
Department of Clinical Pharmacology, Netherlands Cancer Institute, Plesmanlaan 121, P.O. Box 1066 CX, Amsterdam, The Netherlands ; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, P.O. Box 90440, 1006 BK Amsterdam, The Netherlands.
Department of Development and Regeneration, KU Leuven, Herestraat 49, 300 Leuven, Belgium ; Neonatal Intensive Care Unit, University Hospitals Leuven, Herestraat 49, 300 Leuven, Belgium.
Biomed Res Int. 2014;2014:897216. doi: 10.1155/2014/897216. Epub 2014 Feb 3.
This work describes a first population pharmacokinetic (PK) model for free and total cefazolin during pregnancy, which can be used for dose regimen optimization. Secondly, analysis of PK studies in pregnant patients is challenging due to study design limitations. We therefore developed a semiphysiological modeling approach, which leveraged gestation-induced changes in creatinine clearance (CrCL) into a population PK model. This model was then compared to the conventional empirical covariate model. First, a base two-compartmental PK model with a linear protein binding was developed. The empirical covariate model for gestational changes consisted of a linear relationship between CL and gestational age. The semiphysiological model was based on the base population PK model and a separately developed mixed-effect model for gestation-induced change in CrCL. Estimates for baseline clearance (CL) were 0.119 L/min (RSE 58%) and 0.142 L/min (RSE 44%) for the empirical and semiphysiological models, respectively. Both models described the available PK data comparably well. However, as the semiphysiological model was based on prior knowledge of gestation-induced changes in renal function, this model may have improved predictive performance. This work demonstrates how a hybrid semiphysiological population PK approach may be of relevance in order to derive more informative inferences.
这项研究描述了首个妊娠期游离和总头孢唑林的群体药代动力学(PK)模型,该模型可用于优化给药方案。其次,由于研究设计的局限性,对孕妇PK研究的分析具有挑战性。因此,我们开发了一种半生理建模方法,将妊娠引起的肌酐清除率(CrCL)变化纳入群体PK模型。然后将该模型与传统的经验协变量模型进行比较。首先,开发了一个具有线性蛋白结合的基础二室PK模型。妊娠变化的经验协变量模型包括CL与妊娠年龄之间的线性关系。半生理模型基于基础群体PK模型和一个单独开发的关于妊娠引起的CrCL变化的混合效应模型。经验模型和半生理模型的基线清除率(CL)估计值分别为0.119 L/min(相对标准误差58%)和0.142 L/min(相对标准误差44%)。两个模型对现有PK数据的描述都相当好。然而,由于半生理模型基于妊娠引起的肾功能变化的先验知识,该模型可能具有更好的预测性能。这项研究证明了混合半生理群体PK方法如何可能有助于得出更有信息量的推论。